Studies were included if they involved cancer patients treated with ICIs, assessed the prognostic significance of baseline CEA levels or CEA level changes, and reported at least one outcome metric, including overall survival (OS), progression-free survival (PFS), disease control rate (DCR), pathological complete response (pCR), or objective response rate (ORR). This evidence concerns the gene CEACAM5 and cancer.